Clinical trial
Efficacy and Safety of Sintilimab Combined With Platinum-containing Chemotherapy in Neoadjuvant Treatment of Resectable Stage ⅡB~ⅢA Non-small Cell Lung Cancer
NCT05170581 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Shandong First Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Sintilimab Combined With Platinum-containing Chemotherapy in Neoadjuvant Treatment of Resectable Stage ⅡB~ⅢA Non-small Cell Lung Cancer
- Lead sponsor
- The Second Affiliated Hospital of Shandong First Medical University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 1, 2021
- Completion date
- November 30, 2024
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer